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Abstract 
Background 
Amyloid plaque and tau-containing neurofibrillary tangles are important features of 
Alzheimer’s Disease (AD). However, the relationship between these processes is still 
debated.  
Objective 
We aimed to investigate local and distant relationships between tau and amyloid deposition in 
the cortex in Mild Cognitive Impairment (MCI) and AD using PET imaging. 
Methods 
Seventy-nine subjects (fifty-one controls, thirteen amyloid-positive MCI subjects and fifteen 
amyloid positive AD subjects) underwent MRI and 18F-flutemetamol PET. All MCI/AD 
subjects and eight healthy controls as well as thirty-three healthy control subjects from the 
ADNI dataset also had 18F-AV1451 PET. Regional and distant correlations were examined 
after sampling target-to-cerebellar ratio images. Biological parametric mapping was used to 
evaluate voxel level correlations locally. 
Results 
We found multiple clusters of voxels with highly significant positive correlations throughout 
the association cortex in both MCI and AD subjects.  
Conclusion 
The multiple clusters of positive correlations indicate that tau and amyloid may interact 
locally and be involved in disease progression. Our findings suggest that targeting both 
pathologies may be required. 
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Introduction 
Amyloid β (Aβ) plaques and tau-containing neurofibrillary tangles (NFTs) have been 
consistently described as cardinal features of Alzheimer’s disease (AD)[1]. While the 
presence of both is required for a pathological diagnosis of AD, the exact interaction is still 
debated. 
Aβ has a central role in AD: by definition, plaques are necessary but not sufficient for a 
diagnosis of AD [2]. NFTs are also required for a diagnosis [1]. However, NFT aggregation 
increases with age almost universally, but can occasionally be found in healthy individuals 
under 30 years [3, 4]. Thus, isolated medial temporal tauopathy is not sufficient to cause AD 
[4]. This suggests that while Aβ plaques and tau tangles are both required to cause AD, 
neither is sufficient by itself.  
PET imaging allows us to evaluate both these processes. 18F-flutemetamol and 18F-florbetapir 
are amyloid tracers, while 18F-AV1451 has nanomolar affinity for paired helical filament-
tau[5]. PET also enables us to correlate these processes at a voxel level using biological 
parametric mapping (BPM) analysis in SPM[6]. 
We hypothesised that tau aggregation would correlate at voxel level with amyloid levels in 
the isocortex, and that tau aggregation in the medial temporal lobe structures would correlate 
with amyloid in the isocortex. We further hypothesised that there will be local correlation 
between tau and amyloid in different cortical regions. 
Methods 
Standard Protocol Approvals, Registrations and Patient Consents 
Ethical approval was obtained from local and national ethics committees (The Riverside 
Research Ethics Committee – National Health Research Services, Health Research Authority, 
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UK.) The approval for administration of radioactive activity was given by the Administration 
of Radioactive Substances Advisory Committee (ARSAC). Written informed consent was 
obtained from all subjects. 
Recruitment 
Subjects were recruited from memory clinics, a national dementia recruitment website and 
advertisements in local media. All subjects underwent a screening visit consisting of history, 
physical and neurological examination and neuropsychological testing. The clinical diagnosis 
of MCI or AD was re-confirmed applying the Petersen[7] and NINCDS-ADRDA (National 
Institute of Neurological and Communicative Disorders and Stroke and the Alzheimer’s 
disease and Related Disorders Association (NINCDS-ADRDA) criteria, respectively [8, 9]. 
Inclusion criteria were: 1) A diagnosis of MCI as defined by the Petersen criteria, or AD as 
defined by NINCDS-ADRDA criteria, or normal cognition for the healthy controls. 2) Age 
range 50-85 years. 3) Ability to give informed consent. 4) At least 8 years of formal 
education. 5) MMSE above 24 for MCI, above 15 for AD, and normal cognition for healthy 
control subjects. Exclusion criteria were: 1) Major depression, or any significant disease 
influencing neuropsychological testing. 2) A history of schizophrenia/schizoaffective 
disorder. 3) Contraindication to MRI scanning. 4) A malignancy within the last 5 years. 
ADNI database 
In order to ensure a sufficiently large group of normal controls (only eight controls from our 
centre had 18F-AV1451 scans), thirty- three healthy control subjects were drawn from the 
ADNI database (http://adni.loni.usc.edu/). Selection criteria included subjects who had had 
amyloid and tau imaging, and age range between 65-75 years old. All subjects gave written 
informed consent. 
Image acquisition 
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ADNI controls 
A description of the MRI, 18F-AV45 and 18F-AV1451 data acquisition for the thirty-three 
controls from the ADNI database is available on the ADNI website (http://www.adni-
info.org/Scientists/ADNIStudyProcedures.aspx). Only the 18F-AV1451 scans for these 
individuals were used in the correlation and group analyses, as these individuals had different 
amyloid PET scans from our cohort (18F-florbetapir scans were used in the ADNI controls, 
and 18F-flutemetamol used in our centre).  
MRI 
Subjects recruited at our centre had Magnetic Resonance Imaging (MRI) with a 3 Tesla 
Siemens 32-channel Verio scanner.  A T1-weighted magnetisation prepared rapid gradient 
echo sequence (MPRAGE; time repetition = 2400 ms, time echo = 3.06 ms, flip angle of 9, 
inversion time = 900 ms, matrix = [256 x 246]) with a 1 mm3 voxel size, anteroposterior 
phase encoding direction, and a symmetric echo was used. Two subjects with coronary artery 
stents (who were ineligible for 3 Tesla MRI) underwent 1.5 Tesla MRI in a Philips Achieva 
system (Best, Netherlands) at the MRC Clinical Sciences Centre, Imperial College London. 
18F-flutemetamol 
18F-flutemetamol was manufactured by GE Healthcare, Amersham, UK, and scans were 
performed at Imperial College Clinical Imaging Facility using a Siemens Biograph 6 scanner 
with a 15cm field of view. A mean dose of 183.4(±5.3) MBq 18F-flutemetamol in 8ml saline 
was injected followed by a 5-10ml saline flush. Data was acquired in 3D list mode from 90 to 
120 minutes following injection and re-binned as 6x5 minute frames. Image reconstruction 
was performed by filtered back projection with attenuation correction. Post reconstruction 
5mm Gaussian smoothing was applied (The zoom was 2.6, the matrix size was 168x168 and 
the pixel size was 1.56mm x 1.56mm x 1.92mm). 
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18F-AV1451 (flortaucipir) 
18F-AV1451 was manufactured at Imanova Centre for Imaging Sciences, London, and scans 
were acquired using a Siemens Truepoint PET/CT (axial field of view of 21.8cm; 111 
transaxial planes; spatial resolution of 2.056mm x 2.056 mm x 2 mm after image 
reconstruction.  A mean dose of 168.3(±7.4) MBq 18F-AV1451 in 20 ml saline was injected. 
Data was acquired in 3D list mode for 120 minutes and the data was rebinned at the 
following time frames: 8x15 seconds, 3x 60 seconds, 5x120 seconds, 5x300 seconds, 8x600 
seconds. Data reconstruction was performed by iterative reconstruction and 5mm Gaussian 
smoothing post reconstruction. 
Image processing 
Image processing was performed with Analyze AVW 11.0 and SPM (Statistical parametric 
mapping software; Wellcome Trust Centre for Neuroimaging, University College London) on 
a Matlab platform. Scans were pre-processed in Analyze AVW. Voxel level correlations were 
performed using the Biological Parametric Mapping toolbox, which is integrated into SPM5 
software. Regional correlations were calculated using SPSS version 24.0 (IBM), using a 
statistical threshold of significance of 0.05. 
Creation of ratio images for 18F-flutemetamol and 18F AV1451 
The 90-120 minute summed PET image for 18F-flutemetamol and 80-100 minute summed 
PET image for 18F-AV1451 were co-registered to the T1-weighted MRI and were then 
transformed into standard Montreal Neurologic Institute (MNI) space. In order to create an 
object map for each subject, each individual MRI was segmented in Analyze AVW into grey 
matter, white matter and cerebrospinal fluid (CSF). Grey matter voxels were those that had a 
>50% probability of containing grey matter and were used to create an individual grey matter 
binarised image. This individual grey matter binarised image was then convolved with the 
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Hammers probabilistic atlas[10] to create an individualised object map. This object map was 
then applied to the normalised PET to quantify the uptake in the cerebellum. RATIO images 
were then created by dividing the individual PET image by the uptake of cerebellar grey 
matter to create a target to cerebellar RATIO image. The ratio image was then sampled for 
individual regions. 
Voxel level examination of tracer binding 
SPM8 was used to perform independent t-tests on the data (p-value <0.05, no extent 
threshold) to distinguish voxel level tracer uptake between the MCI/AD groups and the 
control group, using the normalised ratio images for 18F-AV1451 and 18F-flutemetamol.  
Creation of Z-score maps and voxel-level correlations using biological parametric 
mapping 
Voxel level correlations between 18F-AV1451 and 18F-flutemetamol were examined using the 
biological parametric mapping toolbox in SPM written on a Matlab (Mathworks Inc) 
platform[6].  Z-score maps were created for each subject, for each tracer, to demonstrate the 
specific increase in tracer uptake compared to the control group. Generating a Z-score 
parametric map allows multi-modal comparison of different tracers, representing the level of 
each pathology relative to the control group. In addition, it accounts for non-specific binding 
seen in these tracers. The Z-score was calculated using the following formulae: 
Z score [18F-flutemetamol] = (18F-flutemetamol ratio image of patient– mean 18F-
flutemetamol ratio image of control group)/standard deviation of 18F-flutemetamol ratio 
image for control group  
Z score [18F-AV1451] = (18F-AV1451 ratio image of patient– mean 18F-AV1451 ratio image 
of control group)/standard deviation of 18F-AV1451 ratio image control group 
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Individual Z-score 18F-flutemetamol and 18F-AV-1451 maps were then interrogated in BPM 
toolbox in order to localise clusters of positive correlation between the uptake of the two 
tracers. Results were corrected for family wise error. All clusters with a corrected p-value of 
p<0.05 with an extent threshold of 1000 voxels were considered significant.  
Single subject SPM analysis 
Individualised tracer uptake on a ‘single subject’ basis was performed using an independent t-
test in SPM, compared to the control group. This allowed us to identify clusters of 
significantly increased tracer uptake in each individual. 
Region of interest analysis 
Region of interest (ROI) analysis of the RATIO images was performed by sampling the 
following regions - anterior cingulate, posterior cingulate, temporal, frontal, parietal and 
occipital lobes. Correlations were considered significant if the p-value was < 0.05. Group 
comparisons were examined using the Kruskal-Wallis test. Regional correlations were 
interrogated using Spearman rho correlation coefficient, using continuous variables (SUVR 
values for 18F-flutemetamol and 18F-AV1451 for each region). Spearman rho correlation 
coefficient was used rather than Pearson coefficient because of the small number of 
participants used in the study. 
Only MCI and AD subjects with positive amyloid scans were included in this study, because 
we wanted to examine the relationship between increasing amyloid load and tau deposition. 
Furthermore, we wanted to examine the underlying processes in individuals on the AD 
trajectory. Amyloid status was defined as positive if there was binding above the recently 
published cut-off of SUVR 1.42 in one or more of the regions described above (anterior 
cingulate, posterior cingulate, frontal, temporal, parietal and occipital lobes).[11] Tau status 
was considered positive if binding was above the threshold of 1.32 in the temporal lobe 
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structures (hippocampus, parahippocampus, amygdala, fusiform gyrus), whole temporal lobe, 
parietal, frontal or occipital lobe. [11] 
Results 
Demographics 
In total, seventy-nine subjects participated in the study (fifty-one healthy controls, thirteen 
amyloid-positive MCI subjects and fifteen amyloid-positive AD subjects). Eighteen controls 
were recruited at our centre at Imperial College London (all had 18F-flutemetamol and eight 
of these had 18F-AV1451 scans). Additionally the scans of thirty-three healthy controls were 
used from the ADNI database for 18F-AV1451 (these participants also had MMSE, MRI 
scans and 18F-AV45 (18F-florbetapir scans). Subjects recruited from our centre had 
neuropsychometric testing, T1-weighted MRI and 18F-flutemetamol. Table 1a shows the age 
and MMSE scores for the cohort. Table 1b shows the neuropsychometric data for the subjects 
recruited at our centre.  
Voxel level increases in tau aggregation and amyloid deposition in MCI and AD 
Figure 1 shows the voxel-level increases in 18F-flutemetamol and 18F-AV1451 in the MCI 
and AD groups compared to the controls  
 
We were interested particularly in the relationships and correlations in the MCI group, and so 
we examined the spatial distribution of amyloid and tau in each individual MCI subject. 
Figure 2 shows the distribution of amyloid and tau aggregation in the six MCI individuals 
who had voxel level significant increases in tau aggregation compared with the controls on 
independent t-test. The amount and density of both amyloid deposition and tau aggregation 
varied in these MCI individuals, demonstrating the heterogeneity of the pathological load in 
these individuals. 
	   	   	  
	  
	   13	  
Regional level increases in amyloid and tau in MCI and AD 
Individual SUVR values for each subject are shown in Supplementary Figures 1 (for 18F-
Flutemetamol), Supplementary Figure 2 (for 18F-AV1451) and Supplementary Figure 3 
(individuals recruited from the ADNI database). Both the MCI and AD groups demonstrated 
significantly increased 18F-flutemetamol uptake in the fusiform gyrus, anterior and posterior 
cingulate cortex, temporal frontal, parietal and occipital cortices. (Supplementary Table 1) 
The AD group had significantly higher 18F-AV1451 retention in the hippocampus, fusiform 
gyrus, amygdala, parahippocampus, temporal, frontal, parietal and occipital cortices. The 
MCI group had higher 18F-AV1451, retention than the controls in the hippocampus, fusiform 
gyrus, amygdala, and parahippocampus. (Supplementary Table 2) 
Voxel level correlations between amyloid and tau aggregation in the cortex  
There were multiple clusters of highly significant positive correlations between 18F-AV1451 
and 18F-Flutemetamol in both MCI and AD (shown in Figure 3 and Table 2). In the MCI 
group, the clusters of strongest correlation (that is Z-scores over 4) were in the frontal and 
temporal cortices, and subcortical structures (corpus callosum, thalamus and caudate). In the 
AD group the largest clusters of strong correlation were in the frontal lobe.  Z-scores and 
correlation coefficients were higher in the positive correlation clusters in the MCI group 
compared with those in the AD group. 
Regional level correlations between amyloid and tau aggregation in the cortex 
In the AD group, there was a positive correlation in the amygdala (r=0.588, p=0.035) but no 
correlations in the MCI group. 
 
Discussion 
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This is the first study to our knowledge to examine in vivo voxel level correlations between 
amyloid deposition and tau aggregation in MCI subjects compared with AD subjects. We 
found highly significant clusters of positive correlations throughout the cortex in both MCI 
and AD. Z-scores and r correlation coefficients were higher in the MCI group than the AD 
group, which may be due to the plateauing of amyloid deposition at the MCI stage, while 
NFT aggregation continues to intensify as the disease progresses [2, 12, 13]. 
At a regional level, we did not find correlations either locally or in cortical projections in the 
MCI group. In the AD group, there were correlations in the amygdala only. This was an 
unexpected finding, and possibly reflects the heterogeneity of the disease process, 
particularly at the MCI stage. Our groups may have been underpowered to detect the 
differences in the processes and correlations.  Finally, it is possible that the regions that we 
were analysing were too large to detect voxel level processes. 
Our findings are in line with histopathological findings of AD brains showing that amyloid 
and tau coexist within neurons in AD [14] consistent with the voxel-level correlations seen in 
our study. It is possible that the two processes occur independently, but in close proximity to 
each other, as tau propagation both locally and across the cortex can occur independently of 
amyloid. [15] 
There is evidence, however, that the processes act synergistically in driving disease 
progression. Tau transgenic (rThTauEC) mice (which overexpress tau in the medial temporal 
lobe) crossed with amyloid transgenic mice (APP/PS1) show a significantly higher tau load 
with propagation throughout the cortex when cortical Aβ is present[16]. Injecting brain 
extracts from amyloid transgenic mice into tau transgenic mice results in spreading of tau 
from the hippocampus to projection at more distant sites. In human neural cell cultures, 
inhibition of Aβ formation reduces tauopathy [17] further implicating amyloid in inducing 
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tau aggregation. The voxel level correlations, suggesting local aggregation, may also point to 
local toxicity between the two processes. In vitro studies have shown that Aβ induces tau 
fibrillisation by cross-seeding, and enhances existing tau aggregation. The possibility of this 
process occurring across specific networks could explain the spatial discordance between 
these two pathologies [18], networks involving the hippocampus providing a transport 
mechanism for tau while those involving the cingulate transport Aβ aggregates.  
Similarly, tau can promote amyloid pathology. The presence of tau aggregates can enhance 
Aβ toxicity[19], which in turn exerts its toxicity by neuronal projections. Injecting 
phosphorylated tau from AD brains into transgenic AD mice (3xTg; mutations to APP, 
Presenilin 1 and MAPT 1) not only induced tau aggregation and propagation, but also 
increased amyloid plaque load (compared with injection of saline). [20] The same group 
found that passive immunisation of monoclonal antibodies to tau into AD transgenic mice not 
only decreased total tau and phosphorylated tau, but also decreased amyloid precursor protein 
(APP) levels and amyloid plaque.[21] This suggests that passive immunisation to tau could 
target both pathologies, thus breaking the disease cycle and halting disease progression.  
In humans, it is suggested that isocortical amyloid may be required to induce slow developing 
medial temporal lobe NFTs to become rapidly spreading toxic NFT aggregates in the 
isocortex [22, 23]. Thus, while the processes can appear to be spatially discordant, there may 
be multiple neuronal projections connecting these ‘discordant’ areas. For example, 
corticocortical evoked potential studies in humans have revealed connections between the 
hippocampus and temporal lobe structures; the parahippocampus and posterior cingulate 
cortex; and between the amygdala and the temporal, frontal, inferior parietal, cingulate, and 
insula [24]. Evoked intracranial EEG responses in humans have suggested multiple 
connections between lobes – with a high frequency of connections within the temporal and 
frontal lobes[25].  
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It is likely that while these processes can occur independently, they also act synergistically 
and have been described as a ‘toxic pas de deux’. [26] 
Study strengths and limitations 
A strength of this study was that our individuals with MCI and AD were well characterised 
and showed amyloid positivity on PET. This allowed us to evaluate tau aggregation in 
homogenous groups of individuals. Additionally, interrogation for both regional and voxel-
level correlations revealed the full extent of spatial associations between the two processes. 
A limitation of the study was the inclusion of small numbers of individuals in each disease 
group, so caution needs to be applied when we generalise our results to the MCI and AD 
populations. Additionally, the inclusion of both tau positive and tau negative MCI individuals 
in the correlation analysis introduces the possibility of false positive results arising from null 
data points. If we had larger numbers we would have performed separate correlation analyses 
for tau-positive and all patients, respectively. However, we felt that it was important to 
include all individuals in this case, as tau deposition is a continuous process in the AD 
trajectory. 
Another consideration is the reported off-target binding of 18F-AV1451 described in the 
choroid plexus, basal ganglia, retinal tissue and melanin containing cells[27-29] so our results 
should be interpreted with caution. However, the use of individualised Z-maps reduces this 
problem. While our findings are in line with previous histopathological studies [14], ideally 
our findings should be confirmed with autoradiographic studies. Additionally, detection of 
correlated tracer binding is influenced by the sensitivity of PET radioligands and is liable to 
false negatives [30]. Amyloid PET imaging can only confidently detect amyloid plaques at 
Thal stage 3 or higher when the load is moderate or severe and consistently misses Thal 
stages 1 and 2. Individuals who are labelled as amyloid negative PART (Primary-age related 
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tauopathy) based on PET imaging may have Aβ that is below the threshold for detection[30]. 
Alternatively, they may enter an amyloidogenic pathway after NFTs aggregate in the medial 
temporal lobes [31, 32]. Another consideration is our chosen cut-offs for amyloid and tau 
positivity, based on previous models by Jack et al. [11] Amyloid and tau deposition are 
continuous processes. In particular, tau deposition increases in the medial temporal lobes in 
normal ageing, and thresholds for biomarker positivity are still debated. Thus, positivity 
depends on the threshold used. Additionally, both amyloid and tau can be present in healthy 
controls.[33, 34]. In view of the limited numbers and the older age of the cohort, we did not 
differentiate between preclinical AD stages 0, 1 and 2 when creating Z-scores for our disease 
groups. If we had only used individuals with preclinical AD stage 0, higher levels of tracer 
uptake in the MCI and AD group would be likely. 
Additionally, we included a subset of 18F-AV1451 scans for healthy controls recruited from 
the ADNI database. These individuals had amyloid scans, but using a different tracer from 
our centre (18F-florbetapir, compared to 18F-flutemetamol) so direct comparison of amyloid 
was not possible. Additionally, the 18F-AV1451 scans were performed on different scanners, 
increasing the possibility of introducing variability into the cohort. 
Here we report for the first time that correlations between amyloid and tau are stronger in 
MCI compared with AD. This is consistent with the fact that both pathologies are increasing 
in MCI but then amyloid deposition plateaus, while NFT aggregation continues to progress 
with the clinical course. However, a longitudinal study would allow us to better establish the 
temporal relationship between these processes, and the sequence of events.  
Conclusion  
In this PET study of MCI and AD subjects, we found that amyloid deposition and tau 
aggregation were significantly correlated at a voxel level across association cortex, in both 
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MCI and AD. Our findings reinforce the view that the two pathological processes are 
synergistic when contributing to AD. The strong correlations in the MCI group may suggest 
that both these pathological processes are still evolving in the MCI stage. Any future 
therapeutic strategy may need to target both of these pathologies.  
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Tables  
Table 1a Demographic data of study participants. Values are mean (standard deviation)  
 Controls MCI AD 
Age 70.68(7.57) 76.08(5.15) 72.10(7.40) 
MMSE 29.44(1.05) 28.15(1.21) 21.87(3.58) 
 
Table 1b Neuropsychometric data of the subjects recruited at our centre. Values are mean 
(standard deviation) * p<0.05, ** p<0.01 
Test Controls (n=18) MCI (n=13) AD (n=15) 
Rey delayed 18.18(7.12) 9.58(7.35)* 3.67(5.59)** 
Logical delayed 27.36(5.94) 10.11(5.32)** 4.46(5.99)** 
Hopkins delayed 
recall 
10.15(2.11) 2.31(1.75)** 1.46(1.90)** 
Hopkins Recognition 
Index 
11.29(1.07) 7.54(3.02)** 4.54(3.43)** 
Semantic fluency 21.00(6.13) 14.23(4.09)** 11.85(5.43)** 
Verbal fluency 49.36(10.80) 39.92(10.84) 34.08(14.85)** 
Digit span 19.07(3.45) 18.38(7.01) 13.46(4.72)* 
Letter number 
sequencing 
11.08(3.09) 7.15(2.41)** 4.62(3.48)** 
Trail Making A 35.54(11.17) 61.23(29.73) 112.82(125)* 
Trail Making B 71.50(21.39) 186.54(110.57)** 165.33(69)* 
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Table 2 Voxel level correlations between 18F-flutemetamol and 18F-AV1451 in MCI and AD 
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Region Coordinates Z-score R 
correlation 
coefficient 
p-value Cluster 
size 
Left presubgenual 
frontal cortex 
-1 37 -7 5.23 0.970 <0.00001 170741 
Corpus callosum -6 25 -3 5.17 0.970 
Right middle 
frontal gyrus 
18 43 -9 4.96 0.960 
Left middle frontal 
gyrus 
-17 32 4 4.85 0.960 
Right thalamus 8 -4 4 4.58 0.940 
Right presubgenual 
frontal cortex 
6 32 -4 4.49 0.940 
Left caudate 
nucleus 
-15 12 8 4.46 0.930 
Left posterior 
temporal lobe 
-26 -34 6 4.37 0.930 
Right subgenual 
frontal cortex 
1 29 -6 4.33 0.930 
Left putamen -16 6 -7 4.3 0.920 
Left thalamus -16 -18 2 4.08 0.910 
Left insula -23 20 6 4.02 0.900 
Left middle frontal 
gyrus 
-53 21 29 3.54 0.850 <0.00001 25919 
Left inferior 
frontal gyrus 
-56 33 10 3.25 0.820 
Left precentral 
gyrus 
-50 -2 40 3.15 0.800 
Left superior 
frontal gyrus 
-15 59 35 3.12 0.800 
Left superior -60 4 -12 3.71 0.870 <0.00001 11721 
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temporal gyrus 
anterior part 
Left insula -41 -1 -9 2.76 0.740 
Left postcentral 
gyrus 
-66 -12 22 2.62 0.720 
Left middle and 
inferior temporal 
gyrus 
-69 -16 -14 2.55 0.700 
Left superior 
temporal gyrus, 
posterior part 
-53 0 -8 2.4 0.670 
Left anterior 
temporal lobe, 
lateral part 
-58 8 -27 2.2 0.630 
Left postcentral 
gyrus 
-60 -16 34 1.98 0.580 
Right superior 
frontal gyrus 
18 -11 58 4.24 0.920 0.030 6020 
Right precentral 
gyrus 
29 -13 51 3.19 0.810 
Alzheimer’s disease 
Left middle frontal 
gyrus 
-22 21 11 4.34 0.900 <0.00001 173296 
Right posterior 
temporal lobe 
28 -35 -3 4.29 0.890 
Left caudate 
nucleus 
-16 15 9 4.28 0.890 
Corpus callosum -11 32 2 4.25 0.890 
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Clusters of voxel-wise positive correlations between 18F-flutemetamol and 18F-AV1451 in 
MCI and AD subjects (clusters > 1000 voxels only) 
 
Funding:  
Left insula -24 -27 8 4.14 0.880 
Right subgenual 
frontal cortex 
4 19 -13 4.13 0.880 
Right caudate 14 14 16 4.08 0.870 
Right middle 
frontal gyrus 
16 38 -5 3.98 0.860 
Right thalamus 14 -23 -1 3.97 0.860 
Left superior 
parietal gyrus 
-36 -39 45 3.9 0.860 
Left insula -34 -26 -5 3.87 0.850 
Right substantia 
nigra 
8 -14 -11 3.76 0.840 
Right superior 
frontal gyrus 
4 29 52 3.75 0.840 
Right precentral 
gyrus 
7 -16 60 3.75 0.840 
Left thalamus -9 -19 -5 3.75 0.840 
Right inferior 
frontal gyrus 
61 18 15 2.4 0.630 
Right precentral 
gyrus 
62 9 15 1.81 0.490 
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Figure legends and captions 
Figure 1: Voxel level increases in 18F-flutemetamol and 18F-AV1451 in the MCI and AD 
groups compared to the controls 
Figure 2: Individual subject increases in amyloid and tau in the MCI group 
Figure 3: Voxel level correlations between amyloid deposition and tau aggregation in MCI 
and AD 
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